TY - JOUR
T1 - American Society of Hematology 2019 guidelines for sickle cell disease
T2 - Cardiopulmonary and kidney disease
AU - Liem, Robert I.
AU - Lanzkron, Sophie
AU - Coates, Thomas D.
AU - DeCastro, Laura
AU - Desai, Ankit A.
AU - Ataga, Kenneth I.
AU - Cohen, Robyn T.
AU - Haynes, Johnson
AU - Osunkwo, Ifeyinwa
AU - Lebensburger, Jeffrey D.
AU - Lash, James P.
AU - Wun, Theodore
AU - Verhovsek, Madeleine
AU - Ontala, Elodie
AU - Blaylark, Rae
AU - Alahdab, Fares
AU - Katabi, Abdulrahman
AU - Mustafa, Reem A.
N1 - Funding Information:
The authors thank M. Hassan Murad from the Mayo Clinic Evidence-Based Practice Research Program for guidance regarding development of these guidelines and writing of the manuscript, as well as Starr Webb and Robert Kunkle from ASH for their assistance with coordination of the guideline development effort.
Funding Information:
The work of this panel was coordinated with 4 other guideline panels (addressing other aspects of SCD) by ASH and the Mayo Evidence-Based Practice Research Center (funded by ASH under a paid agreement). Project oversight was provided by a coordination panel, which reported to the ASH Guideline Oversight Subcommittee. ASH vetted individuals and appointed them to the guideline panel. The Mayo Center vetted and retained researchers to conduct systematic reviews of evidence and coordinate the guideline development process, including the use of the GRADE approach. The membership of the panels and the Mayo Center team is described in supplemental File 1.
Funding Information:
Members of the guideline panel received travel reimbursement for attendance at in-person meetings, and the patient representatives received honoraria of $100 per day for in-person meetings and $25 per conference call. The panelists received no other payments. Through the Mayo Clinic Evidence-Based Practice Research Program, some researchers who contributed to the systematic evidence reviews received salary or grant support. Other researchers participated to fulfill requirements of an academic degree or program.
Publisher Copyright:
© 2019 by The American Society of Hematology.
PY - 2019
Y1 - 2019
N2 - Background: Prevention and management of end-organ disease represent major challenges facing providers of children and adults with sickle cell disease (SCD). Uncertainty and variability in the screening, diagnosis, and management of cardiopulmonary and renal complications in SCD lead to varying outcomes for affected individuals. Objective: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in their decisions about screening, diagnosis, and management of cardiopulmonary and renal complications of SCD. Methods: ASH formed a multidisciplinary guideline panel that included 2 patient representatives and was balanced to minimize potential bias from conflicts of interest. The Mayo Evidence-Based Practice Research Program supported the guideline development process, including performing systematic evidence reviews up to September 2017. The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, including GRADE evidence-to-decision frameworks, to assess evidence and make recommendations, which were subject to public comment. Results: The panel agreed on 10 recommendations for screening, diagnosis, and management of cardiopulmonary and renal complications of SCD. Recommendations related to anticoagulation duration for adults with SCD and venous thromboembolism were also developed. Conclusions: Most recommendations were conditional due to a paucity of direct, high-quality evidence for outcomes of interest. Future research was identified, including the need for prospective studies to better understand the natural history of cardiopulmonary and renal disease, their relationship to patient-important outcomes, and optimal management.
AB - Background: Prevention and management of end-organ disease represent major challenges facing providers of children and adults with sickle cell disease (SCD). Uncertainty and variability in the screening, diagnosis, and management of cardiopulmonary and renal complications in SCD lead to varying outcomes for affected individuals. Objective: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in their decisions about screening, diagnosis, and management of cardiopulmonary and renal complications of SCD. Methods: ASH formed a multidisciplinary guideline panel that included 2 patient representatives and was balanced to minimize potential bias from conflicts of interest. The Mayo Evidence-Based Practice Research Program supported the guideline development process, including performing systematic evidence reviews up to September 2017. The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, including GRADE evidence-to-decision frameworks, to assess evidence and make recommendations, which were subject to public comment. Results: The panel agreed on 10 recommendations for screening, diagnosis, and management of cardiopulmonary and renal complications of SCD. Recommendations related to anticoagulation duration for adults with SCD and venous thromboembolism were also developed. Conclusions: Most recommendations were conditional due to a paucity of direct, high-quality evidence for outcomes of interest. Future research was identified, including the need for prospective studies to better understand the natural history of cardiopulmonary and renal disease, their relationship to patient-important outcomes, and optimal management.
UR - http://www.scopus.com/inward/record.url?scp=85076336575&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076336575&partnerID=8YFLogxK
U2 - 10.1182/bloodadvances.2019000916
DO - 10.1182/bloodadvances.2019000916
M3 - Article
C2 - 31794601
AN - SCOPUS:85076336575
SN - 2473-9529
VL - 3
SP - 3867
EP - 3897
JO - Blood Advances
JF - Blood Advances
IS - 23
ER -